Keywords: Javelin, Dyloject, Therabel, Batch withdrawal, NSAID
Javelin slumps 35% as European partner Therabel withdraws batches of Dyloject
Article | 25 May 2010
USA-based Javelin Pharmaceuticals, the subject of a $145 million takeover bid from Hospira, saw its shares plummet 25% to $1.35 in morning trading ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
